von Willebrand factor A domain containing 3AGenealiases: []
Q-omics provides the consensus-scored VWA3A profile across patient tissues and cancer cell-line models. VWA3A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VWA3A is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, VWA3A RNA expression shows 17,328 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUAD, and UVM as cancer lineages where VWA3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VWA3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VWA3A survival associations across molecular data types. VWA3A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VWA3A RNA expression–survival associations across cancer types. High VWA3A expression shows unfavorable associations in KIRC and COAD, but favorable associations in ESCA, BLCA, CESC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VWA3A RNA expression.
This table summarizes VWA3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VWA3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VWA3A shows lower tumor expression in LUAD, LUSC, KICH, COAD and THCA and higher tumor expression in CHOL. The LUAD box plot shows higher VWA3A RNA expression in normal versus tumor tissue (log2 FC = −1.579, t-test p < 0.001).
This table shows molecular features associated with VWA3A in patient tissues and cancer cell lines. In patient samples, VWA3A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VWA3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
